N@N

Market Maker Surveillance Report. MWW, ATHX, ARNA, HPOL, TSRA, NVGN, Losing Stocks With Lowest Price Friction For Friday, Janu

^{Published on 2011-01-28 17:51:23 - WOPRAI}
 

January 28, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 2046 companies with "abnormal" market making, 1289 companies with positive Friction Factors and 4567 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Friday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. MONSTER WORLDWIDE INC (NYSE:MWW), ATHERSYS INC (NASDAQ:ATHX), ARENA PHARMACEUTICALS INC (NASDAQ:ARNA), HARRIS INTERACTIVE INC (NASDAQ:HPOL), TESSERA TECHNOLOGIES INC (NASDAQ:TSRA), NOVOGEN LIMITED-SPONS ADR (NASDAQ:NVGN). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     MWW        $-5.420      -25.36%      8,916,872       41.90%       9,635,954       45.28%       -719,082        -1,327  
     ATHX       $-0.430      -14.53%      207,191         39.55%       316,737         60.45%       -109,546        -2,548  
     ARNA       $-0.390      -19.50%      4,081,265       40.00%       6,094,762       59.74%       -2,013,497      -51,628 
     HPOL       $-0.290      -21.32%      57,672          28.42%       145,243         71.58%       -87,571         -3,020  
     TSRA       $-4.100      -19.33%      1,166,197       41.70%       1,517,995       54.28%       -351,798        -858    
     NVGN       $-0.200      -16.00%      104,991         30.47%       239,582         69.53%       -134,591        -6,730  

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows NVGN with a dollar loss Friday of $-0.20000 and a Friction Factor of -6,730 shares. That means that it only took 6,730 more shares of selling than buying to move NVGN lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

MONSTER WORLDWIDE INC (NYSE:MWW) - Monster Worldwide, Inc., together with its subsidiaries, provides online employment solutions in North America, Europe, and Asia. The company operates a network of Websites that connect employers and jobseekers. Its online recruiting and employment services and solutions include searchable job postings, resume database, recruitment media solutions, and other career related content. The company also offers premium career services at a fee to job seekers, such as resume writing and resume distribution service, as well as enables employers and human resources companies to post jobs, search resume database, and utilize career site hosting and other services. In addition, it provides Internet advertising services, including content, services, and offerings that enable consumers to manage the development and direction of their current and future careers, while offering employers, educators, and marketers with media-driven solutions. Monster Worldwide serves individuals, small and medium-sized organizations, enterprise organizations, and educational institutions, as well as federal, state, and local government agencies. The company was founded in 1967 and is based in New York, New York.

ATHERSYS INC (NASDAQ:ATHX) - Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products in various disease areas in the United States. Its product pipeline includes MultiStem, a novel allogeneic approach to stem cell therapy and regenerative medicine for treating a range of diseases. The company also develops orally active pharmaceutical products for the treatment of obesity and certain central nervous system disorders, including narcolepsy, excessive daytime sleepiness, and chronic fatigue, as well as other potential indications consisting of attention deficit hyperactivity disorder and other cognitive disorders, including schizophrenia. It has product co-development collaboration with Angiotech Pharmaceuticals, Inc. for the potential application of MultiStem in multiple cardiovascular indications, including myocardial infarction, peripheral vascular disease, and certain other indications. In addition, the company has a collaboration agreement with Pfizer Inc. to develop and commercialize MutiStem for the treatment of inflammatory bowel disease. Athersys, Inc. was founded in 1995 and is based in Cleveland, Ohio.

ARENA PHARMACEUTICALS INC (NASDAQ:ARNA) - Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company also discovers small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its clinical development programs include lorcaserin that has completed Phase III clinical trials for the treatment of weight management; APD791, an anti-thrombotic drug candidate, which completed Phase Ia and Phase Ib clinical trials; APD597 that is in Phase I clinical trials for the treatment of type II diabetes; APD916, which has completed preclinical development for the treatment of narcolepsy and cataplexy; and APD811, a preclinical drug candidate for the treatment of pulmonary arterial hypertension. The companys drug candidates use GPCR-focused drug discovery and development approach, as well as technologies, including Constitutively Activated Receptor Technology and Melanophore Technology. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. to further develop compounds for the potential treatment of type II diabetes and other disorders; and Merck & Co., Inc. to develop therapeutics for atherosclerosis and other disorders. Arena Pharmaceuticals also has a strategic cooperation agreement with Siegfried Ltd to manufacture lorcaserin. The company was founded in 1997 and is based in San Diego, California.

HARRIS INTERACTIVE INC (NASDAQ:HPOL) - Harris Interactive Inc. operates as a consultative market research company primarily in North America, Europe, and Asia. It provides market research and polling services, which include ad-hoc or customized qualitative and quantitative research, service bureau research, and long-term tracking studies. The company also offers consultative solutions in the areas of market assessment, product development, brand and communications, reputation management, stakeholder relationships, and youth and education; and conducts computer-assisted telephone interviewing in telephone data collection centers. In addition, it conducts various types of custom research, including customer satisfaction surveys, market share studies, new product introduction studies, brand recognition studies, reputation studies, and ad concept testing. Further, the company involves in the design, execution, and maintenance of custom and online tracking studies for clients in a range of industries; and conducts data collection for other market research firms. It serves automotive, transportation, travel, tourism, energy, professional services, consumer goods, financial services, healthcare, public affairs and policy, technology, media, and telecommunication sectors. The company has a collaboration agreement with Ideas To Go Inc. to offer clients complementary capabilities that build upon one another's work. Harris Interactive Inc. was founded in 1956 and is headquartered in New York, New York.

TESSERA TECHNOLOGIES INC (NASDAQ:TSRA) - Tessera Technologies Inc. develops and licenses miniaturization technologies for chip-scale, multichip, and wafer-level packaging, which enables companies to produce chips for digital audio players, digital cameras, personal computers, personal digital assistants, video game consoles, and mobile phones. The 17-year-old company also manufactures wafer optics in small volumes. Its related services run from engineering (such as customized package design, modeling, simulation, failure analysis, and reliability testing) to assembly (training and consulting to help semiconductor assemblers keep assembly lines up to date) and infrastructure (evaluation, qualification, cost reduction, and cost analysis for companies that supply equipment and materials to chipmakers). Customers include chipmakers and assemblers, system manufacturers, electronic manufacturing service companies, and government agencies and their contractors. Tessera is based in San Jose, Calif.

NOVOGEN LIMITED-SPONS ADR (NASDAQ:NVGN) - Novogen Limited and its subsidiaries engage in the research and development of pharmaceutical products, and marketing of consumer healthcare products. The companys consumer healthcare products comprise Promensil, a range of natural products specifically for womens health; Vinalac, a probiotic formula to help prevent childhood allergies, such as eczema in children at risk of an allergy; Aliten for weight control; and Trinovin, for the enhancement and maintenance of mens health. It focuses on oncology, cardiovascular, dermatological, and anti-inflammatory programs. The companys programs include Phenoxodiol, a phase III investigational drug for late stage, chemoresistant ovarian cancer and prostate, and cervical cancers; Triphendiol, a phase I signal transduction inhibitor for the treatment of cholangiocarcinoma or bile duct cancer, and stage IIB through stage IV malignant melanoma; NV-128, a pre-clinical stage cancer compound to promote cancer cell death in multidrug resistant ovarian cancer cells by targeting the AKT-mTOR pathway; and GLYC-101, a phase II product for the treatment of wounds following laser ablation, burn wounds, surgical wounds, venous ulcers, and diabetic ulcers. Novogens programs also include NV-143, a derivative of triphendiol and a pan acting ant-cancer; NV-04, a program for cardiovascular disease; NV-27, an oral agent to prevent arterial restenosis following coronary artery angioplasty; and NV-07 for the protection of mice against UV-induced inflammatory changes in the skin and against UV-induced skin immune suppression. In addition, it develops NV-52 for the treatment of inflammatory bowel disease; and FAIMs, flavonoid anti-inflammatory molecules to avoid cardiovascular, gastrointestinal, and renal side effects associated with anti-inflammatory drugs. Novogen Limited offers its products in Australia, North America, and Europe. The company was founded in 1994 and is headquartered in North Ryde, Australia.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net